Drug Evaluation Committee Points to keep in mind regarding support for investigator-initiated clinical research under the influence (coronary disaster) of novel coronavirus infection (COVID-19)
Medical Affairs Subcommittee
We understand that each company is taking measures in relation to the outbreak of new coronavirus infection in 2020.
Japan Pharmaceutical Manufacturers Association (JPMA) member companies also need to take appropriate measures for clinical research as well as clinical trials and clinical studies, while implementing measures to prevent the spread of infection.
The Medical Affairs Subcommittee has issued the "Points to Consider Regarding Support for Investigator-Initiated Clinical Research under the Influence of New Coronavirus Infections (COVID-19) (Coronavirus Disaster)," and we would like to ask all concerned parties to share this information widely.
October 19, 2020
Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association
Medical Affairs Subcommittee